Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy

Simple Summary We demonstrated the possible occurrence of the hypersensitivity to low dose (HRS) phenomenon in SBRT modality in both tumor and healthy cells. In HRS-positive cells, the response to SBRT was found exacerbated. Notably, a subset of highly damaged cells can appear and increase the efficiency of the treatment. Hence, each SBRT session can be viewed as hyperfractionated dose delivery by means of hundreds of low dose minibeams. To determine the HRS status of tumors and healthy tissues appears to be useful to increase SBRT efficiency and decrease the risk of adverse reactions. Stereotactic body radiation therapy (SBRT) has made the hypofractionation of high doses delivered in a few sessions more acceptable. While the benefits of hypofractionated SBRT have been attributed to additional vascular, immune effects, or specific cell deaths, a radiobiological and mechanistic model is still needed. By considering each session of SBRT, the dose is divided into hundreds of minibeams delivering some fractions of Gy. In such a dose range, the hypersensitivity to low dose (HRS) phenomenon can occur. HRS produces a biological effect equivalent to that produced by a dose 5-to-10 times higher. To examine whether HRS could contribute to enhancing radiation effects under SBRT conditions, we exposed tumor cells of different HRS statuses to SBRT. Four human HRS-positive and two HRS-negative tumor cell lines were exposed to different dose delivery modes: a single dose of 0.2 Gy, 2 Gy, 10 x 0.2 Gy, and a single dose of 2 Gy using a non-coplanar isocentric minibeams irradiation mode were delivered. Anti-& gamma;H2AX immunofluorescence, assessing DNA double-strand breaks (DSB), was applied. In the HRS-positive cells, the DSB produced by 10 x 0.2 Gy and 2 Gy, delivered by tens of minibeams, appeared to be more severe, and they provided more highly damaged cells than in the HRS-negative cells, suggesting that more severe DSB are induced in the SBRT modes conditions when HRS occurs in tumor. Each SBRT session can be viewed as hyperfractionated dose delivery by means of hundreds of low dose minibeams. Under current SBRT conditions (i.e., low dose per minibeam and not using ultra-high dose-rate), the response of HRS-positive tumors to SBRT may be enhanced significantly. Interestingly, similar conclusions were reached with HRS-positive and HRS-negative untransformed fibroblast cell lines, suggesting that the HRS phenomenon may also impact the risk of post-RT tissue overreactions.

Automated summary

We demonstrated the occurrence of hypersensitivity to low dose (HRS) phenomenon in both tumor and healthy cells in SBRT modality. The response to SBRT was found to be exacerbated in HRS-positive cells, leading to the appearance of a subset of highly damaged cells that can enhance the treatment efficiency. It is important to determine the HRS status of tumors and healthy tissues to increase SBRT efficiency and reduce the risk of adverse reactions.